X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12787) 12787
Book Review (2028) 2028
Publication (677) 677
Conference Proceeding (43) 43
Magazine Article (15) 15
Book Chapter (14) 14
Book / eBook (11) 11
Dissertation (9) 9
Newsletter (6) 6
Web Resource (3) 3
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12078) 12078
humans (11777) 11777
antimetabolites, antineoplastic - therapeutic use (7942) 7942
female (6665) 6665
male (6294) 6294
oncology (5177) 5177
middle aged (5096) 5096
aged (4717) 4717
antimetabolites, antineoplastic - administration & dosage (3942) 3942
adult (3656) 3656
chemotherapy (3426) 3426
deoxycytidine - analogs & derivatives (3387) 3387
cancer (2828) 2828
antineoplastic combined chemotherapy protocols - therapeutic use (2797) 2797
treatment outcome (2755) 2755
fluorouracil - therapeutic use (2698) 2698
antimetabolites, antineoplastic - adverse effects (2602) 2602
deoxycytidine - therapeutic use (2248) 2248
animals (2165) 2165
pharmacology & pharmacy (1815) 1815
fluorouracil - administration & dosage (1775) 1775
antimetabolites, antineoplastic - pharmacology (1764) 1764
5-fluorouracil (1717) 1717
aged, 80 and over (1589) 1589
gemcitabine (1472) 1472
combined modality therapy (1335) 1335
fluorouracil (1312) 1312
deoxycytidine - administration & dosage (1286) 1286
therapy (1268) 1268
prognosis (1238) 1238
mice (1222) 1222
pancreatic neoplasms - drug therapy (1141) 1141
carcinoma (1131) 1131
survival analysis (1059) 1059
capecitabine (1057) 1057
adenocarcinoma - drug therapy (1055) 1055
care and treatment (1048) 1048
neoplasm staging (1048) 1048
retrospective studies (1045) 1045
colorectal neoplasms - drug therapy (1023) 1023
antineoplastic agents - therapeutic use (1017) 1017
survival rate (1013) 1013
hematology (1006) 1006
chemotherapy, adjuvant (999) 999
medicine & public health (999) 999
drug administration schedule (981) 981
cell line, tumor (977) 977
disease-free survival (958) 958
deoxycytidine - adverse effects (919) 919
drug combinations (913) 913
survival (895) 895
surgery (869) 869
methotrexate (856) 856
fluorouracil - adverse effects (845) 845
time factors (838) 838
methotrexate - therapeutic use (827) 827
fluorouracil - analogs & derivatives (823) 823
research (811) 811
antimetabolites, antineoplastic - pharmacokinetics (806) 806
antineoplastic combined chemotherapy protocols - adverse effects (800) 800
dose-response relationship, drug (793) 793
pancreatic cancer (770) 770
abridged index medicus (767) 767
analysis (755) 755
follow-up studies (755) 755
radiotherapy (755) 755
neoplasms - drug therapy (740) 740
trial (730) 730
lung neoplasms - drug therapy (726) 726
tegafur - therapeutic use (707) 707
colorectal cancer (705) 705
adolescent (698) 698
breast neoplasms - drug therapy (695) 695
apoptosis (693) 693
cisplatin (681) 681
antineoplastic agents - administration & dosage (665) 665
cisplatin - administration & dosage (659) 659
tumors (655) 655
expression (646) 646
toxicity (631) 631
remission induction (624) 624
pancreatic neoplasms - pathology (622) 622
methotrexate - administration & dosage (612) 612
oxonic acid - therapeutic use (602) 602
azacitidine - therapeutic use (599) 599
stomach neoplasms - drug therapy (598) 598
antineoplastic agents (592) 592
child (573) 573
fluorouracil - pharmacology (571) 571
health aspects (569) 569
drug therapy (566) 566
drug resistance, neoplasm (563) 563
administration, oral (545) 545
phase-ii (541) 541
prospective studies (533) 533
adenocarcinoma (527) 527
antimitotic agents (523) 523
colorectal neoplasms - pathology (520) 520
gastroenterology & hepatology (519) 519
apoptosis - drug effects (518) 518
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11175) 11175
Japanese (766) 766
French (244) 244
German (174) 174
Chinese (103) 103
Russian (78) 78
Italian (76) 76
Spanish (74) 74
Dutch (21) 21
Polish (18) 18
Hungarian (15) 15
Korean (15) 15
Czech (11) 11
Portuguese (7) 7
Bulgarian (6) 6
Lithuanian (6) 6
Norwegian (6) 6
Ukrainian (6) 6
Danish (5) 5
Hebrew (5) 5
Swedish (5) 5
Finnish (4) 4
Romanian (3) 3
Serbian (3) 3
Croatian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 18, pp. 1691 - 1703
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2895 - 2902
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 3, pp. 215 - 221
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2799 - 2805
Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of... 
Advanced pancreatic cancer | Gemcitabine | Sorafenib | Phase III randomized trial | MULTICENTER | MONOTHERAPY | sorafenib | SOLID TUMORS | BEVACIZUMAB | ADENOCARCINOMA | BRAF INHIBITORS | COMBINATION | RAF/MEK/ERK PATHWAY | CHEMOTHERAPY | phase III randomized trial | ONCOLOGY | gemcitabine | ONCOLOGY GROUP | advanced pancreatic cancer | Niacinamide - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Placebos | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Deoxycytidine - administration & dosage | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Niacinamide - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Ribonucleotide Reductases - antagonists & inhibitors | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 749 - 759
Summary Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | COLON-CANCER | 1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | BEVACIZUMAB | PROSPECTIVE MOLECULAR STRATIFICATION | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN | COMBINATION | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Colorectal Neoplasms - enzymology | Camptothecin - therapeutic use | Drug Administration Schedule | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | United Kingdom | Chi-Square Distribution | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Clinical trials | Care and treatment | Antineoplastic agents | Colorectal cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 14, pp. 1273 - 1281
Journal Article